Lumigan Versus Cosopt

Pharmaceutical Research Network3 sites in 1 country34 target enrollmentJanuary 2006

ConditionsOpen-Angle Glaucoma

Drugsbimatoprost 0.03%dorzolamide 2%/timolol maleate 0.5% fixed combination placebo

Overview

Phase: Phase 4
Intervention: Not specified
Conditions: Open-Angle Glaucoma
Sponsor: Pharmaceutical Research Network
Enrollment: 34
Locations: 3
Status: Completed
Last Updated: 17 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

To compare the intraocular pressure effect and safety of the dorzolamide/timolol fixed combination given twice daily versus bimatoprost given once every evening in patients with open-angle glaucoma in patients insufficiently controlled on latanoprost monotherapy

Registry

clinicaltrials.gov

Start Date

January 2006

End Date

May 2007

Last Updated

17 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Pharmaceutical Research Network

Eligibility Criteria

Inclusion Criteria

•adults with a diagnosis of bilateral open-angle glaucoma including: primary, pigment dispersion or exfoliation in both eyes
•on no therapy the intraocular pressure should be 22-29 mm Hg inclusive at the 8:00 AM measurement
•visual acuity should be 20/200 or better in each eye

Exclusion Criteria

•historical failure to respond to topical beta-blockers in a clinically meaningful manner
•any contraindication to study medications
•any anticipated change, or modification in the 6 weeks prior to Visit 1, in systemic hypertensive therapy during the trial